A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach

References

• American Cancer Society. Esophagus Cancer. Available from: https://www.cancer.org/cancer/esophagus-cancer.html [accessed 2016 Mar 25]
   Google Scholar
• Murphy AG, Lynch D, Kelly RJ. State of the art management of metastatic gastroesophageal cancer. Ann Transl Med. 2015;3:236.
   PubMedGoogle Scholar
• Louvet C, André T, Tigaud JM, Gamelin E, Douillard JY, Brunet R, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol. 2002;20:4543–4548.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol. 2004;22:658–663.
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol. 2010;28:4006.
   PubMed Web of Science ®Google Scholar
• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–925.
   PubMed Web of Science ®Google Scholar
• Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H, Tahara E. Frequent amplification of the c-Met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun. 1992;189:227–232.
   PubMed Web of Science ®Google Scholar
• Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, et al. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene. 2006;25:409–418.
   PubMed Web of Science ®Google Scholar
• Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 2008;7:3499–3508.
   PubMed Web of Science ®Google Scholar
• Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011;17:7754–7764.
   PubMed Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55–63.
   PubMed Web of Science ®Google Scholar
• Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29:3307–3315.
   PubMed Web of Science ®Google Scholar
• Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, et al. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012;118:5903–5911.
   PubMed Web of Science ®Google Scholar
• Koeppen H, Januario T, Filvaroff E, Towne P, James R, Roche P, et al. Characterization and clinical validation of an immunohistochemical assay for Met in non-small cell lung cancer. Presented at the 101st Annual Meeting of the United States and Canadian Academy of Pathology; March 17–23, 2012; Vancouver, British Columbia, Canada. ( abstr 2001)
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. US Department of Health and Human Services; 2010.
   Google Scholar
• Eisenhauer E, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New Response Evaluation Criteria in Solid Tumors: Revised RECIST Guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;5:457–481.
   Google Scholar
• Feldman DR, Einhorn LH, Quinn DI, Loriot Y, Joffe JK, Vaughn DJ, et al. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013;31:1016–22.
   PubMed Web of Science ®Google Scholar
• Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:,draft55–63.
   PubMed Web of Science ®Google Scholar
• Dumontet C, Jordan MA. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790–803.
   PubMed Web of Science ®Google Scholar
• Xu YP, Lin G, Sun XJ, Yan MH, Zhang G, Hu JL, et al. c-Met as a molecular marker for esophageal squamous cell carcinoma and its association with clinical outcome. J Cancer. 2016;7:587–594.
   PubMed Web of Science ®Google Scholar
• Wang H, Jiang D, Song Q, Xu C, Shi Y, Li X, et al. Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma. Tumour Biol. 2016;37:9771–9779. DOI: 10.1007/s13277-015-4692-4
   PubMed Web of Science ®Google Scholar
• Fuse N, Kuboki Y, Kuwata T, et al. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 2016;19:183–191.
   PubMed Web of Science ®Google Scholar
• Kwak EL, LoRusso P, Hamid O, Janku F, Kittaneh M, Virgil D, et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. J Clin Oncol. 2015;33(suppl 3):1.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209.
   PubMed Web of Science ®Google Scholar
• Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014;15:1007–1018.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Tebbutt NC, Davidenko I, Murad AM, Al-Batran S-E, Ilson DH, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. 2015;33:4000.
   Web of Science ®Google Scholar
• Shah MA, Cho JY, Huat ITB, Tebbutt NC, Yen C-J, Kang A, et al. Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC). J Clin Oncol. 2015;33:2.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Phase 2 study of AMG 337 in MET amplified gastric/esophageal adenocarcinoma or other solid tumors. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02016534 [accessed 2016 Jul 15]
   Google Scholar
• Strickler JH, Nemunaitis JJ, Weekes CD, Ramanathan RK, Angevin E, Morgensztern D, et al. Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors. J Clin Oncol. 2016;34:2510.
   Web of Science ®Google Scholar